CytRx (CYTR) vs. Acorda Therapeutics (ACOR) Head to Head Comparison

CytRx (NASDAQ:CYTR) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CytRx and Acorda Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytRx 0 0 1 0 3.00
Acorda Therapeutics 2 5 2 0 2.00

CytRx currently has a consensus target price of $5.00, indicating a potential upside of 879.24%. Acorda Therapeutics has a consensus target price of $21.25, indicating a potential upside of 81.01%. Given CytRx’s stronger consensus rating and higher probable upside, research analysts plainly believe CytRx is more favorable than Acorda Therapeutics.

Institutional & Insider Ownership

9.9% of CytRx shares are owned by institutional investors. 6.6% of CytRx shares are owned by company insiders. Comparatively, 7.8% of Acorda Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares CytRx and Acorda Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CytRx N/A -40.81% -25.51%
Acorda Therapeutics -1.40% 9.19% 4.32%

Risk & Volatility

CytRx has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Earnings & Valuation

This table compares CytRx and Acorda Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CytRx $250,000.00 68.71 -$12.71 million ($0.29) -1.76
Acorda Therapeutics $471.43 million 1.20 $33.68 million $1.82 6.45

Acorda Therapeutics has higher revenue and earnings than CytRx. CytRx is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Acorda Therapeutics beats CytRx on 8 of the 14 factors compared between the two stocks.

About CytRx

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

About Acorda Therapeutics

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.